vismodegib
vismodegib: developed by 1 company · 5 clinical trials tracked.
vismodegib evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
How could vismodegib → CRIS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| CURIS INC (CRIS) Treatment of adults with metastatic basal cell carcinoma (BC… | Approved |
Clinical Trials (5)
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Primary endpoint: Time to Treatment Failure
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial
Primary endpoint: Objective response rate defined as the number of patients with complete response or partial response
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile
Primary endpoint: Percentage of patients that are treated based on their molecular tumor profile
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Primary endpoint: Progression free survival (PFS)
Molecular Analysis for Therapy Choice (MATCH)
Primary endpoint: Objective response rate (ORR)
Frequently asked questions
Who is developing vismodegib?
vismodegib is being developed by CURIS INC.
How many clinical trials involve vismodegib?
BioSniper tracks 5 clinical trials involving vismodegib.